Molecular monitoring of BAALC expression in patients with CD34-positive acute leukemia
- 8 April 2010
- journal article
- research article
- Published by Springer Nature in International Journal of Hematology
- Vol. 91 (4) , 636-645
Abstract
Recent studies have shown that high BAALC expression predicts an adverse prognosis and may define an important risk factor in acute myeloid leukemia patients with normal karyotype. We performed, using real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR), the molecular analysis of BAALC gene as a possible minimal residual disease (MRD) marker in 45 patients with newly diagnosed acute leukemia. BAALC transcript levels in 32 patients with CD34 expressed in leukemic blasts were 2–3 logs higher than background levels, and the copy number was reduced in patients achieving hematological remission. Comparative monitoring of MRD by RQ-PCR for the Wilms’ tumor gene 1(WT1) or specific translocation markers demonstrated that BAALC had similar kinetics as WT1, AML1/ETO and minor BCR/ABL, but not PML/RARA. Quantitation of BAALC gene expression made it possible to assess MRD in patients with CD34-positive acute leukemia. To our knowledge, this is the first report concerning the use of BAALC mRNA expression for MRD monitoring.Keywords
This publication has 17 references indexed in Scilit:
- High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) studyBlood, 2008
- Low ERG and BAALC Expression Identifies a New Subgroup of Adult Acute T-Lymphoblastic Leukemia With a Highly Favorable OutcomeJournal of Clinical Oncology, 2007
- Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advancesCurrent Opinion in Hematology, 2007
- High Expression of the ETS Transcription Factor ERG Predicts Adverse Outcome in Acute T-Lymphoblastic Leukemia in AdultsJournal of Clinical Oncology, 2006
- Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?Blood, 2006
- Risk Assessment in Patients with Acute Myeloid Leukemia and a Normal KaryotypeClinical Cancer Research, 2005
- Multiplex Real-time RT–PCR for Prospective Evaluation ofWT1and Fusion Gene Transcripts in Newly DiagnosedDe NovoAcute Myeloid LeukemiaLeukemia & Lymphoma, 2004
- BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B StudyBlood, 2003
- Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapySeminars in Hematology, 2003
- The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemiaBlood, 2003